Ganoderic Acids Alleviate Neuroinflammation by Targeting Myeloid Differentiation Factor 2 for Ischemic Stroke Therapy

Abstract

Neuroinflammation plays a critical role in cerebral ischemic injury, making it an important therapeutic target for stroke treatment. Ganoderic acids (GAs), the primary bioactive compounds isolated from Ganoderma lucidum, exhibit well-demonstrated anti-inflammatory properties. This study aimed to investigate the neuroprotective potential of GAs in the context of ischemic stroke. Mice subjected to transient middle cerebral artery occlusion (tMCAO) served as an in vivo model of focal cerebral ischemia, while LPS-treated microglial cells were utilized as an in vitro model to evaluate microglial activation. GAs treatment significantly alleviated cerebral ischemic injury, inhibited microglial overactivation, and decreased inflammatory cytokine expression in both in vitro and in vivo models. Mechanistically, eight principal monomers in GAs, particularly GA-K, were found to target myeloid differentiation protein 2 (MD2), thereby preventing its interaction with Toll-like receptor 4 (TLR4), and subsequently inhibiting MAPK and NF-κB pathways. MD2 was found to be overexpressed under ischemic conditions. In MD2-deficient mice, microglial activation was inhibited, and neuroprotection against ischemic injury was observed, unaffected by GAs. These findings suggest that GAs, particularly GA-K, provide neuroprotection in ischemic stroke by modulating microglia-mediated neuroinflammation through MD2, which may serve as a promising therapeutic target for stroke patients.

Keywords

ganoderic acid / ischemic stroke / microglia / myeloid differentiation protein 2 / neuroinflammation / Toll-like receptor 4

References

[1] GBD 2019 Stroke Collaborators. Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet Neurology 2021, 20, 795–820.

[2] A. Greco, G. Occhipinti, D. Giacoppo, et al., “Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke,” Journal of the American College of Cardiology 82 (2023): 1538–1557, https://doi.org/10.1016/j.jacc.2023.07.025.

[3] P. Widimsky, K. Snyder, J. Sulzenko, L. N. Hopkins, and I. Stetkarova, “Acute Ischaemic Stroke: Recent Advances in Reperfusion Treatment,” European Heart Journal 44 (2023): 1205–1215, https://doi.org/10.1093/eurheartj/ehac684.

[4] Y. Zhao, Q. Li, J. Niu, et al., “Neutrophil Membrane-Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy,” Advanced Materials 36 (2024): e2311803, https://doi.org/10.1002/adma.202311803.

[5] S. Raffaele, E. Thougaard, C. C. H. Laursen, et al., “Microglial TNFR2 Signaling Regulates the Inflammatory Response After CNS Injury in a Sex-Specific Fashion,” Brain, Behavior, and Immunity 116 (2024): 269–285, https://doi.org/10.1016/j.bbi.2023.12.025.

[6] W. Zhang, T. Tian, S. X. Gong, et al., “Microglia-Related Neuroinflammation as a Potential Therapeutic Target in Ischemic Stroke,” Neural Regeneration Research 16 (2021): 6–11.

[7] D. L. Alsbrook, M. Di Napoli, K. Bhatia, et al., “Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke,” Current Neurology and Neuroscience Reports 23 (2023): 407–431, https://doi.org/10.1007/s11910-023-01282-2.

[8] S. Yang, C. Qin, M. Chen, et al., “TREM2-IGF1 Mediated Glucometabolic Enhancement Underlies Microglial Neuroprotective Properties During Ischemic Stroke,” Advancement of Science 11 (2024): e2305614, https://doi.org/10.1002/advs.202305614.

[9] D. J. Newman and G. M. Cragg, “Natural Products as Sources of New Drugs Over the Nearly Four Decades From 01/1981 to 09/2019,” Journal of Natural Products 83 (2020): 770–803, https://doi.org/10.1021/acs.jnatprod.9b01285.

[10] L. X. Liao, X. M. Song, L. C. Wang, et al., “Highly Selective Inhibition of IMPDH2 Provides the Basis of Antineuroinflammation Therapy,” in Proceedings of the National Academy of Science USA 114, no. 29 (2017): E5986–E5994.

[11] M. Jiang, X. Liu, D. Zhang, et al., “Celastrol Treatment Protects Against Acute Ischemic Stroke-Induced Brain Injury by Promoting an IL-33/ST2 Axis-Mediated Microglia/Macrophage M2 Polarization,” Journal of Neuroinflammation 15 (2018): 78, https://doi.org/10.1186/s12974-018-1124-6.

[12] K. Sun, J. Fan, and J. Han, “Ameliorating Effects of Traditional Chinese Medicine Preparation, Chinese Materia Medica and Active Compounds on Ischemia/Reperfusion-induced Cerebral Microcirculatory Disturbances and Neuron Damage,” Acta Pharmaceutica Sinica B 5 (2015): 8–24, https://doi.org/10.1016/j.apsb.2014.11.002.

[13] T. Hao, Y. Yang, N. Li, et al., “Inflammatory Mechanism of Cerebral Ischemia-Reperfusion Injury With Treatment of Stepharine in Rats,” Phytomedicine 79 (2020): 153353, https://doi.org/10.1016/j.phymed.2020.153353.

[14] L. Su, L. Liu, Y. Jia, et al., “Ganoderma Triterpenes Retard Renal Cyst Development by Downregulating Ras/MAPK Signaling and Promoting Cell Differentiation,” Kidney International 92 (2017): 1404–1418, https://doi.org/10.1016/j.kint.2017.04.013.

[15] C. J. Chang, C. S. Lin, C. C. Lu, et al., “Ganoderma Lucidum Reduces Obesity in Mice by Modulating the Composition of the Gut Microbiota,” Nature Communications 6 (2015): 7489, https://doi.org/10.1038/ncomms8489.

[16] S. Dudhgaonkar, A. Thyagarajan, and D. Sliva, “Suppression of the Inflammatory Response by Triterpenes Isolated From the Mushroom Ganoderma Lucidum,” International Immunopharmacology 9 (2009): 1272–1280, https://doi.org/10.1016/j.intimp.2009.07.011.

[17] J. Jiang, B. Grieb, A. Thyagarajan, and D. Sliva, “Ganoderic Acids Suppress Growth and Invasive Behavior of Breast Cancer Cells by Modulating AP-1 and NF-kappaB Signaling,” International Journal of Molecular Medicine 21 (2008): 577–584.

[18] S. Zheng, J. Ma, X. Zhao, X. Yu, and Y. Ma, “Ganoderic Acid A Attenuates IL-1β-Induced Inflammation in Human Nucleus Pulposus Cells Through Inhibiting the NF-κB Pathway,” Inflammation 45 (2022): 851–862, https://doi.org/10.1007/s10753-021-01590-0.

[19] A. Abulizi, L. Hu, A. Ma, et al., “Ganoderic Acid Alleviates Chemotherapy-Induced Fatigue in Mice Bearing Colon Tumor,” Acta Pharmacologica Sinica 42, no. 10 (2021): 1703–1713.

[20] Y. Z. Quan, A. Ma, C. Q. Ren, et al., “Ganoderic Acids Alleviate Atherosclerosis by Inhibiting Macrophage M1 Polarization via TLR4/MyD88/NF-κB Signaling Pathway,” Atherosclerosis 391 (2024): 117478, https://doi.org/10.1016/j.atherosclerosis.2024.117478.

[21] G. Shao, J. He, J. Meng, et al., “Ganoderic Acids Prevent Renal Ischemia Reperfusion Injury by Inhibiting Inflammation and Apoptosis,” International Journal of Molecular Sciences 22 (2021): 13234.

[22] Y. Jiao, T. Xie, L. H. Zou, Q. Wei, L. Qiu, and L. X. Chen, “Lanostane Triterpenoids From Ganoderma curtisii and Their NO Production Inhibitory Activities of LPS-Induced Microglia,” Bioorganic & Medicinal Chemistry Letters 26 (2016): 3556–3561, https://doi.org/10.1016/j.bmcl.2016.06.023.

[23] B. Chi, S. Wang, and S. Bi, “Effects of Ganoderic Acid A on Lipopolysaccharide‑Induced Proinflammatory Cytokine Release From Primary Mouse Microglia Cultures,” Experimental and Therapeutic Medicine 15 (2018): 847–853.

[24] F. Sheng, L. Zhang, S. Wang, L. Yang, and P. Li, “Deacetyl Ganoderic Acid F Inhibits LPS-Induced Neural Inflammation via NF-κB Pathway Both In Vitro and In Vivo,” Nutrients 12 (2019): 85, https://doi.org/10.3390/nu12010085.

[25] X. Q. Geng, A. Ma, J. Z. He, et al., “Ganoderic Acid Hinders Renal Fibrosis via Suppressing the TGF-β/Smad and MAPK Signaling Pathways,” Acta Pharmacologica Sinica 41 (2020): 670–677, https://doi.org/10.1038/s41401-019-0324-7.

[26] H. Lian, E. Roy, and H. Zheng, “Protocol for Primary Microglial Culture Preparation,” Bio-Protocol 6 (2016): e1832.

[27] Y. Li, L. Xu, K. Zeng, et al., “Propane-2-Sulfonic Acid Octadec-9-Enyl-Amide, a Novel PPARα/γ Dual Agonist, Protects Against Ischemia-Induced Brain Damage in Mice by Inhibiting Inflammatory Responses,” Brain, Behavior, and Immunity 66 (2017): 289–301, https://doi.org/10.1016/j.bbi.2017.07.015.

[28] X. Guan, S. Zhu, J. Song, et al., “Microglial CMPK2 Promotes Neuroinflammation and Brain Injury After Ischemic Stroke,” Cell Reports Medicine 5 (2024): 101522, https://doi.org/10.1016/j.xcrm.2024.101522.

[29] C. L. Gao, G. G. Hou, J. Liu, et al., “Synthesis and Target Identification of Benzoxepane Derivatives as Potential Anti-Neuroinflammatory Agents for Ischemic Stroke,” Angewandte Chemie International Edition 59 (2020): 2429–2439, https://doi.org/10.1002/anie.201912489.

[30] J. Song, W. Zhang, J. Wang, et al., “Inhibition of FOXO3a/BIM Signaling Pathway Contributes to the Protective Effect of Salvianolic Acid A Against Cerebral Ischemia/Reperfusion Injury,” Acta Pharmaceutica Sinica B 9 (2019): 505–515, https://doi.org/10.1016/j.apsb.2019.01.010.

[31] X. Chen, L. Chen, G. Lin, et al., “White Matter Damage as a Consequence of Vascular Dysfunction in a Spontaneous Mouse Model of Chronic Mild Chronic Hypoperfusion With eNOS Deficiency,” Molecular Psychiatry 27 (2022): 4754–4769, https://doi.org/10.1038/s41380-022-01701-9.

[32] N. Feng, Y. Wei, J. Feng, et al., “Preparative Isolation of Ganoderic Acid S, Ganoderic Acid T and Ganoderol B From Ganoderma Lucidum Mycelia by High-Speed Counter-Current Chromatography,” Biomedical Chromatography 32 (2018): e4283, https://doi.org/10.1002/bmc.4283.

[33] L. Yang, F. Zhou, Y. Zhuang, et al., “Acetyl-Bufalin Shows Potent Efficacy Against Non-Small-Cell Lung Cancer by Targeting the CDK9/STAT3 Signalling Pathway,” British Journal of Cancer 124 (2021): 645–657, https://doi.org/10.1038/s41416-020-01135-6.

[34] S. Ye, W. Luo, Z. A. Khan, et al., “Celastrol Attenuates Angiotensin II–Induced Cardiac Remodeling by Targeting STAT3,” Circulation Research 126 (2020): 1007–1023, https://doi.org/10.1161/CIRCRESAHA.119.315861.

[35] Y. F. Chen, A. L. Shiau, S. H. Wang, et al., “Zhankuic Acid A Isolated From Taiwanofungus Camphoratus Is a Novel Selective TLR4/MD-2 Antagonist With Anti-Inflammatory Properties,” Journal of Immunology 192 (2014): 2778–2786, https://doi.org/10.4049/jimmunol.1301931.

[36] Y. Liu, C. Zhou, J. Tan, et al., “Ganoderic Acid A Slows Osteoarthritis Progression by Attenuating Endoplasmic Reticulum Stress and Blocking NF-Κb Pathway,” Chemical Biology and Drug Design 103 (2024): e14382, https://doi.org/10.1111/cbdd.14382.

[37] L. Zhang, L. Zhang, and R. Sui, “Ganoderic Acid A-Mediated Modulation of Microglial Polarization Is Involved in Depressive-Like Behaviors and Neuroinflammation in a Rat Model of Post-Stroke Depression,” Neuropsychiatric Disease and Treatment 17 (2021): 2671–2681, https://doi.org/10.2147/NDT.S317207.

[38] Y. Q. Geng, L. N. Qiu, Y. Q. Cheng, et al., “Alleviating Recombinant Tissue Plasminogen Activator-Induced Hemorrhagic Transformation in Ischemic Stroke via Targeted Delivery of a Ferroptosis Inhibitor,” Advancement of Science 11 (2024): e2309517, https://doi.org/10.1002/advs.202309517.

[39] Y. Quan, A. Ma, and B. Yang, “Preventive and Therapeutic Effect of Ganoderma (Lingzhi) on Brain Injury,” Advances in Experimental Medicine and Biology 1182 (2019): 159.

[40] T. Shichita, H. Ooboshi, and A. Yoshimura, “Neuroimmune Mechanisms and Therapies Mediating Post-Ischaemic Brain Injury and Repair,” Nature Reviews Neuroscience 24 (2023): 299–312, https://doi.org/10.1038/s41583-023-00690-0.

[41] L. Sun, D. Chen, C. Zhao, et al., “Echinatin Protects From Ischemic Brain Injury by Attenuating NLRP3-Related Neuroinflammation,” Neurochemistry International 175 (2024): 105676, https://doi.org/10.1016/j.neuint.2024.105676.

[42] O. Jung, A. Thomas, S. R. Burks, et al., “Neuroinflammation Associated With Ultrasound-Mediated Permeabilization of the Blood–Brain Barrier,” Trends in Neuroscience (Tins) 45 (2022): 459–470, https://doi.org/10.1016/j.tins.2022.03.003.

[43] D. D. Liu, P. Luo, L. Gu, et al., “Celastrol Exerts a Neuroprotective Effect by Directly Binding to HMGB1 Protein in Cerebral Ischemia–reperfusion,” J Neuroinflammation 18 (2021): 174, https://doi.org/10.1186/s12974-021-02216-w.

[44] Y. Jia, Y. Tong, L. Min, Y. Li, and Y. Cheng, “Protective Effects of oridonin Against Cerebral Ischemia/Reperfusion Injury by Inhibiting the NLRP3 Inflammasome Activation,” Tissue & Cell 71 (2021): 101514, https://doi.org/10.1016/j.tice.2021.101514.

[45] L. Zhang, Y. Han, X. Wu, et al., “Research Progress on the Mechanism of Curcumin in Cerebral Ischemia/Reperfusion Injury: A Narrative Review,” Apoptosis 28 (2023): 1285–1303, https://doi.org/10.1007/s10495-023-01869-7.

[46] W. X. Zheng, W. Q. He, Q. R. Zhang, et al., “Baicalin Inhibits NLRP3 Inflammasome Activity via the AMPK Signaling Pathway to Alleviate Cerebral Ischemia-Reperfusion Injury,” Inflammation 44 (2021): 2091–2105, https://doi.org/10.1007/s10753-021-01486-z.

[47] Y. Jia, D. Zhang, H. Yin, H. Li, J. Du, and H. Bao, “Ganoderic Acid A Attenuates LPS-Induced Neuroinflammation in BV2 Microglia by Activating Farnesoid X Receptor,” Neurochemical Research 46 (2021): 1725–1736, https://doi.org/10.1007/s11064-021-03303-3.

[48] J. E. Anttila, K. W. Whitaker, E. S. Wires, B. K. Harvey, and M. Airavaara, “Role of Microglia in Ischemic Focal Stroke and Recovery: Focus on Toll-Like Receptors,” Progress in Neuro-Psychopharmacology & Biological Psychiatry 79 (2017): 3–14, https://doi.org/10.1016/j.pnpbp.2016.07.003.

[49] V. Kumar, “Toll-Like Receptors in the Pathogenesis of Neuroinflammation,” Journal of Neuroimmunology 332 (2019): 16–30, https://doi.org/10.1016/j.jneuroim.2019.03.012.

[50] Y. Zhang, T. Xu, Z. Pan, et al., “Shikonin Inhibits Myeloid Differentiation Protein 2 to Prevent LPS-Induced Acute Lung Injury,” British Journal of Pharmacology 175 (2018): 840–854, https://doi.org/10.1111/bph.14129.

[51] Y. Wang, X. Shan, G. Chen, et al., “MD-2 as the Target of a Novel Small Molecule, L6H 21, in the Attenuation of LPS-Induced Inflammatory Response and Sepsis,” British Journal of Pharmacology 172 (2015): 4391–4405, https://doi.org/10.1111/bph.13221.

[52] Y. Zhang, J. Wu, S. Ying, et al., “Discovery of New MD2 Inhibitor From Chalcone Derivatives With Anti-Inflammatory Effects in LPS-Induced Acute Lung Injury,” Scientific Reports 6 (2016): 25130, https://doi.org/10.1038/srep25130.

[53] Y. Zhang, T. Xu, B. Wu, et al., “Targeting Myeloid Differentiation Protein 2 by the New Chalcone L2H21 Protects LPS-Induced Acute Lung Injury,” Journal of Cellular and Molecular Medicine 21 (2017): 746–757, https://doi.org/10.1111/jcmm.13017.

[54] R. Shimazu, S. Akashi, H. Ogata, et al., “MD-2, A Molecule That Confers Lipopolysaccharide Responsiveness on Toll-Like Receptor 4,” Journal of Experimental Medicine 189 (1999): 1777–1782, https://doi.org/10.1084/jem.189.11.1777.

[55] Y. Zhang, H. Chen, W. Zhang, et al., “Arachidonic Acid Inhibits Inflammatory Responses by Binding to Myeloid Differentiation Factor-2 (MD2) and Preventing MD2/Toll-Like Receptor 4 Signaling Activation,” Biochimica et Biophysica Acta — Molecular Basis of Disease 1866 (2020): 165683, https://doi.org/10.1016/j.bbadis.2020.165683.

[56] T. Chen, W. Huang, J. Qian, et al., “Macrophage-Derived Myeloid Differentiation Protein 2 Plays an Essential Role in Ox-LDL-Induced Inflammation and Atherosclerosis,” EBioMedicine 53 (2020): 102706, https://doi.org/10.1016/j.ebiom.2020.102706.

[57] H. Yang, H. Wang, Z. Ju, et al., “MD-2 Is Required for Disulfide HMGB1–Dependent TLR4 Signaling,” Journal of Experimental Medicine 212 (2015): 5–14, https://doi.org/10.1084/jem.20141318.

[58] A. A. de Oliveira, J. Faustino, M. E. de Lima, R. Menezes, and K. P. Nunes, “Unveiling the Interplay between the TLR4/MD2 Complex and HSP70 in the Human Cardiovascular System: A Computational Approach,” International Journal of Molecular Sciences 20, no. 13 (2019): 3121.

[59] T. T. Oo, W. Pratchayasakul, N. Chattipakorn, and S. C. Chattipakorn, “Potential Roles of Myeloid Differentiation Factor 2 on Neuroinflammation and Its Possible Interventions,” Molecular Neurobiology 57 (2020): 4825–4844, https://doi.org/10.1007/s12035-020-02066-2.

[60] M. Bsibsi, R. Ravid, D. Gveric, and J. M. van Noort, “Broad Expression of Toll-Like Receptors in the Human Central Nervous System,” Journal of Neuropathology and Experimental Neurology 61 (2002): 1013–1021, https://doi.org/10.1093/jnen/61.11.1013.

RIGHTS & PERMISSIONS

2026 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.